ExploreWatchlistsPricing
  1. US-listed companies
  2. IMMUNIC, INC.
  3. Financials
  4. Cash and cash equivalents

IMMUNIC, INC. (IMUX)

Market cap
$1.3B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 202516-56.58%
Dec 31, 202436-23.55%
Dec 31, 202347-56.25%
Dec 31, 2022107+22.84%
Dec 31, 202187-31.84%
Dec 31, 2020128+333.67%
Dec 31, 201929+120.65%
Dec 31, 201813-76.58%
Dec 31, 201757-5.15%
Dec 31, 201660-28.08%
Dec 31, 201583-18.41%
Dec 31, 2014102

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat